Immuncell-LC is under clinical development by GC Cell and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Immuncell-LC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Immuncell-LC overview
Immuncell-LC is an anti-cancer immune therapeutic agent, that uses the patient's own lymphocytes, is derived from peripheral blood mononuclear cells and cultured under well-defined culture conditions for 2-3 weeks, has characteristics bearing cytotoxic T-cells (CTL) and CIK cells. It is formulated as injectable solution for intravenous infusion route of administration. Immuncell-LC is indicated for the treatment of hepatocellular carcinoma resection (surgical, high frequency surgery, percutaneous ethanol injection) adjuvant therapy after tumor removal in patients.
Immuncell-LC (GCC4002) is under development for the treatment of pancreatic ductal adenocarcinoma, and adenocarcinoma of the gastroesophageal junction.
The therapeutic candidate was also under development for the treatment of gemcitabine refractory advanced pancreatic cancer, metastatic colorectal cancer, refractory/relapsed neuroblastoma, glioblastoma multiforme (GBM), hepatocellular carcinoma and pancreatic cancer.
GC Cell overview
GC Cell, a subsidiary of GC Biopharma Corp, is a biotechnology company. It develops innovative immune cell therapies to cure challenging diseases. GC Cell offers customized cell therapy solutions to partners, besides CDMO and bio logistics services. The company’s pipeline allogenic products include GCC4001, an AB-101, Naive NK Cell that targets relapsed/ refractory lymphoma, lupus, and relapsed/ refractory Hodgkin’s lymphoma; GCC2003, an AB-201, HER2 CAR-NK for HER2+ solid cancer; and GCC2005 that targets T-cell lymphoma. Its autologous product GCC4002 is an Immuncell-LC, cytokine-induced killer (CIK) cell therapy that targets pancreatic cancer and liver cancer. The company has an operational presence in the US, Japan and South Korea. GC Cell is headquartered in Yongin-si, Gyeonggi-do, South Korea.
For a complete picture of Immuncell-LC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
